Emerging therapies targeting eosinophil-mediated inflammation in chronic allergic conjunctivitis

Andrew Fernandez, Penny Asbell, Neeta Roy

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Ocular allergy remains a significant burden to the population while the treatment for the severe, chronic forms of allergic conjunctivitis remains largely limited to non-specific immunosuppressants. Eosinophils are central to the pathophysiology and sustaining the immunologic response found in the chronic forms of ocular allergy such as vernal keratoconjunctivitis and atopic keratoconjunctivitis. Several mediators of eosinophil recruitment, chemotaxis, adhesion, activation, and survival have been identified that offer potential therapeutic targets for ocular allergy. Based on preclinical and clinical data available in both ocular and non-ocular allergy studies, these emerging therapies warrant further investigation in reducing the severity of disease in patients with chronic ocular allergy.

Original languageEnglish
Pages (from-to)191-196
Number of pages6
JournalOcular Surface
StatePublished - Oct 2022
Externally publishedYes


  • AKC
  • Allergy
  • Conjunctivitis
  • Cornea
  • Eosinophil
  • Mediators
  • Treatment
  • VKC


Dive into the research topics of 'Emerging therapies targeting eosinophil-mediated inflammation in chronic allergic conjunctivitis'. Together they form a unique fingerprint.

Cite this